Showing 7191-7200 of 7494 results for "".
- Patient Savings Program Available for Mylan's Doxycycline Hyclatehttps://practicaldermatology.com/news/20130925-patient_savings_program_available_for_mylans_doxycycline_hyclate/2459450/Patients who are prescribed Mylan's bioequivalent alternative to Doryx (doxycycline hyclate delayed-release tablets) USP for severe acne may be eligible for an instant savings program. Patients who take their prescriptions to participating pharmacies will receive an automatic co-pay reduction at the
- Rosacea Concierge Offers Patient Support and Resourceshttps://practicaldermatology.com/news/20130924-rosacea_concierge_offers_patient_support_and_resources/2459453/Bayer HealthCare recently launched Rosacea Concierge, a new resource for the estimated 16 million people living with rosacea. The new, easy-to-navigate www.RosaceaConcierge.com includes information on rosacea in the form of video tutorials from a team of experts, including a der
- Elevator Pitch Sessions Launching from The Medical Entrepreneurhttps://practicaldermatology.com/news/20130924-elevator_pitch_sessions_launching__from_the_medical_entrepreneur/2459454/The Medical Entrepreneur Symposium is introducing a one day event on Saturday December 7 in Delray Beach. The “Elevator Pitch Sessions” will be geared towards helping physicians learn how to fund their next venture. "We are excite
- Precision Dermatology Names New CEOhttps://practicaldermatology.com/news/20130924-precision_dermatology_names_new_ceo/2459455/Robert J. Moccia has been appointed to the position of Chief Executive Officer at Precision Dermatology Inc. Mr. Moccia has led the introduction of a number of new strategies for growth since joining the company in January of this year. Mr. Moccia has 30 years of experience in dermatology, having mo
- Alma® Lasers Kicks of Nationwide Roadshow, Practice Success Seminarshttps://practicaldermatology.com/news/20130917-alma_kicks_off_nationwide_roadshow/2459458/Alma® Lasers kicks off its Practice for Success series of seminars this week. Seminars, led by aesthetic professionals, will focus on marketing strategies proven to grow aesthetic practices. There are also opportunities for hands-on participat
- ResurFX for M22 Platform from Lumenis Receives FDA Clearancehttps://practicaldermatology.com/news/20130917-resurfx_for_m22_platform_from_lumenis_receives_fda_clearance/2459459/The FDA recently granted 510(k) clearance for ResurFX, a new fractional non-ablative laser module from Lumenis. ResurFX is the latest application module for the company's M22 platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing.
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Exuviance Launches Age Less Everyday Daily Moisturizerhttps://practicaldermatology.com/news/20130912-exuviance_launches_age_less_everydaydaily_moisturizer/2459462/NeoStrata Company, Inc., recently introduced Exuviance Age Less Everyday, a daily moisturizer formulated to correct the signs of aging for skin that is dry, sensitive, or easily impacted by everyday stressors. Exuviance Age Less Everyday is formulated w
- FDA Approves Botox Cosmetic to Treat Crow's Feet Lines in Adultshttps://practicaldermatology.com/news/20130912-fda_approves_botox_cosmetic_to_treat_crows_feet_lines_in_adults/2459463/The FDA recently approved Botox Cosmetic (onabotulinumtoxinA) for an additional indication to temporarily treat moderate to severe lateral canthal lines. Allergan's
- Anacor Submits NDA, Presents Data for Tavaborolehttps://practicaldermatology.com/news/20130830-anacor_submits_nda_presents_data_for_tavaborole/2459469/Anacor Pharmaceuticals has submitted an NDA to the FDA for for Tavaborole, its drug candidate for the topical treatment of onychomycosis. The company recently reported data presented at this summer's 2013 APMA Annual Scientific Meeting. Findings s